Few pharmaceutical products have entered mainstream public consciousness as quickly as GLP-1.

Originally associated primarily with diabetes treatment, medicines such as Ozempic, Wegovy and Mounjaro have become globally recognised through their use in weight management. Demand has grown rapidly, amplified by traditional media, social media and celebrity-driven interest.

The World Health Organisation (WHO) has already warned of increased reports of falsified semaglutide products across multiple regions.[1] It has identified the relationship between increased legitimate customer requirements, constrained availability, and consumers seeking products through unofficial channels as creating opportunities for falsified medicines to enter the market.

GLP-1 receptor agonists such as semaglutide are particularly attractive to illicit markets because they combine established medical use with rapidly growing consumer demand for weight loss. Semaglutide lowers blood glucose, suppresses appetite, and, for certain patients, can reduce the risk of serious cardiovascular events. This creates a large and diverse market that criminal networks can exploit when legitimate access is limited.

This is not simply a falsification or counterfeiting problem.

The emerging GLP-1 market demonstrates how pharmaceutical crime can develop around the economics of a highly desirable medicine. High consumer demand, significant product value and limitations on legitimate access can create precisely the conditions that attract criminal exploitation.

Criminal markets adapt to demand

Criminal markets are rarely static. They identify products consumers are willing to pay for and then find ways to satisfy that requirement.

For GLP-1 medicines, this can take several forms: falsification, theft, diversion from legitimate channels and illicit online supply.

In June 2026, US authorities announced charges concerning an alleged transnational scheme involving counterfeit Ozempic sourced from China and distributed into the United States. Prosecutors claim that counterfeit packaging, labelling and needles were used to make the products appear authentic.[2]

The threat is also increasingly digital. Research published in August 2026 examining illicit GLP-1 trading on Telegram found a persistent market for these medicines, with Ozempic accounting for almost half of identified GLP-1 product mentions. More than half of GLP-1 advertisements examined were alongside illicit drugs.[3]

These are important signals.

They suggest that the distinction between traditional illicit drug markets and pharmaceutical crime may be becoming increasingly blurred.

The risk extends across the supply chain

The attraction of GLP-1 medicines does not begin or end online.

Products with high demand and resale value may become attractive targets at multiple points: manufacturing, wholesale distribution, transportation, pharmacies and ultimately patients.

BSI (British Standards Institution) has highlighted this convergence, describing how GLP-1 criminal networks can mirror legitimate pharmaceutical supply chains. In February 2026, for example, more than 1,600 units of tirzepatide were reportedly stolen from a truck in Paraguay Such thefts therefore pose risks that extend well beyond the immediate loss. Stolen products may be stored, transported and resold outside controlled conditions, undermining traceability and temperature assurance while creating opportunities for substitution, relabelling or integration into illicit supply chains.

The implication is significant. Organisations cannot view falsification, cargo theft, diversion and illicit online sales as unrelated problems. They may represent different stages or manifestations of the same criminal marketplace.

Following the market, not simply the product

GLP-1 medicines provide a valuable lesson for pharmaceutical crime prevention.

The question should not only be: Which products are currently being falsified or stolen?

It should also be: Which products are becoming attractive to criminals next?

Rapidly increasing demand, shortages, high resale values, restricted access, social-media visibility and growing illicit online availability can all provide early indicators of emerging criminal opportunity.

That requires organisations to move from reacting to incidents towards identifying the conditions that make particular products vulnerable.

Because criminals do not need to understand pharmaceutical strategy.

They need to understand markets.

And when legitimate customer requirements create scarcity, value and opportunity, criminal markets are often ready to respond.

Prevention | Intelligence | Investigation | Organisational Resilience

[1] https://www.who.int/news/item/20-06-2024-who-issues-warning-on-falsified-medicines-used-for-diabetes-treatment-and-weight-loss

[2] https://www.justice.gov/criminal/criminal-vns/case/united-states-v-swapnadip-roy-and-vicky-ramancha

[3] https://link.springer.com/article/10.1007/s12117-026-09613-8

[4] https://www.bsigroup.com/en-GB/insights-and-media/insights/blogs/cargo-theft-crisis-fuels-global-counterfeit-glp-1-market/